- Home
- EKSO vs BCDA Comparison
EKSO vs BCDA Comparison
Compare EKSO & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EKSO
- BCDA
- Stock Information
- Founded
- EKSO 2005
- BCDA N/A
- Country
- EKSO United States
- BCDA United States
- Employees
- EKSO N/A
- BCDA N/A
- Industry
- EKSO Medical/Dental Instruments
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- EKSO Health Care
- BCDA Health Care
- Exchange
- EKSO Nasdaq
- BCDA Nasdaq
- Market Cap
- EKSO 11.6M
- BCDA 9.4M
- IPO Year
- EKSO N/A
- BCDA N/A
- Fundamental
- Price
- EKSO $0.44
- BCDA $1.97
- Analyst Decision
- EKSO Strong Buy
- BCDA Strong Buy
- Analyst Count
- EKSO 2
- BCDA 1
- Target Price
- EKSO $5.00
- BCDA $25.00
- AVG Volume (30 Days)
- EKSO 107.1K
- BCDA 91.7K
- Earning Date
- EKSO 05-06-2025
- BCDA 05-13-2025
- Dividend Yield
- EKSO N/A
- BCDA N/A
- EPS Growth
- EKSO N/A
- BCDA N/A
- EPS
- EKSO N/A
- BCDA N/A
- Revenue
- EKSO $17,925,000.00
- BCDA $58,000.00
- Revenue This Year
- EKSO $25.17
- BCDA N/A
- Revenue Next Year
- EKSO $37.02
- BCDA N/A
- P/E Ratio
- EKSO N/A
- BCDA N/A
- Revenue Growth
- EKSO N/A
- BCDA N/A
- 52 Week Low
- EKSO $0.34
- BCDA $1.63
- 52 Week High
- EKSO $1.53
- BCDA $6.15
- Technical
- Relative Strength Index (RSI)
- EKSO 55.45
- BCDA 44.53
- Support Level
- EKSO $0.39
- BCDA $1.73
- Resistance Level
- EKSO $0.43
- BCDA $1.93
- Average True Range (ATR)
- EKSO 0.04
- BCDA 0.13
- MACD
- EKSO 0.01
- BCDA -0.00
- Stochastic Oscillator
- EKSO 92.45
- BCDA 70.59
About EKSO Ekso Bionics Holdings Inc.
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).